Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q1 2018 · 10-Q
Revenue$4.81M$4.81M+38.6% vs Q1 2017 Net Income-$3.28M-$3.28MN/M vs Q1 2017 EPS Diluted-$0.11-$0.11N/M vs Q1 2017 Gross Profit$2,229,000+31.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flow-$2,494,000N/M Free Cash Flowderived-$2,554,000— Margins · derivedGross margin46.4%−2.6 pt vs Q1 2017
Operating margin-67.5%−174.1 pt vs Q1 2017
Net margin-68.1%−135.3 pt vs Q1 2017
ended Mar 31, 2018 · filed May 15, 2018 · 45 d after period end